Rena Brand, MD
Dermatology · New York, NYNPI 1538168935
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 57.5% of the total. 2025 is the largest year on record at $114, 8.5 times the $14 reported in 2022. That places this record below the midpoint for dermatology clinicians in NY, where the typical reported total is $2,360.
Across 9 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$130
- AbbVie$67
- Galderma Laboratories, L.p.$15
- Incyte Corporation$14
What the payments were for
- Food & beverage$226100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 4 | $130 |
| AbbVie | 3 | $67 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Incyte Corporation | 1 | $14 |
How this compares
$226 in reported general payments places this provider in the 15th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metronidazole | 383 | $18,006 |
| Ketoconazole | 691 | $11,292 |
| Azelaic Acid | 69 | $9,632 |
| Fluocinonide | 183 | $6,486 |
| Clobetasol Propionate | 79 | $4,210 |
| Fluocinonide-EFluocinonide/Emollient Base | 63 | $3,740 |
| Triamcinolone Acetonide | 317 | $3,436 |
| Clindamycin Phosphate | 71 | $2,813 |
| Mupirocin | 360 | $2,778 |
| Hydrocortisone | 208 | $1,687 |
| Econazole Nitrate | 54 | $1,678 |
| Tretinoin | 23 | $1,366 |
| Gentamicin Sulfate | 20 | $976 |
| Permethrin | 13 | $844 |
| Mometasone Furoate | 47 | $703 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New York
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Joshua ZeichnerNew York$2.1M
- Emma GuttmanNew York$1.7M
- George HanNew York$1.6M
- Amy SpizuocoNew York$1.3M
- Andrew AlexisNew York$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.